Co-Fluampicil Oral Suspension 125 Mg/125 Mg In 5 Ml
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Co-Fluampicil Oral Suspension 125/125mg/5ml
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Flucloxacillin Sodium BP equivalent to Flucloxacillin 125mg/5ml Ampicillin Trihydrate BP equivalent to Ampicillin BP 125mg/5ml
3 PHARMACEUTICAL FORM
A free flowing powder in two layers the top layer being white, the bottom layer being off-white.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Treatment of severe infections where the causative organism is unknown, and for mixed infections involving “Resistant” staphylococci.
In general practice the elixir can be used for chest infections, ENT infections, soft tissue infections and patients with an underlying pathology which makes them more susceptible to infections.
In hospital use, if laboratory tests are not yet available, it can be used for severe respiratory infections, post-operative chest and wound infections, septic abortion and puerperal fever. Septicaemia. Prophylaxis in major surgery and infections in patients receiving immunosuppressive therapy;
The products spectrum makes it suitable for the treatment of many mixed infections, particularly those where penicillinase-producing staphylococci are suspected or confirmed.
Posology and method of administration
4.2
Adults (including elderly patients)
10 ml four times a day;
Children
5ml four times a day;
The above dosages may be doubled where necessary and should be administered half an hour to one hour before meals.
Route of administration
Oral
4.3 Contraindications
Ocular administration.
Co-fluampicil contains ampicillin and flucloxacillin which are penicillins, and should not be given to patients with a history of hypersensitivity to P-lactam antibiotics (e.g. penicillins, cephalosporins).
Co-fluampicil is contraindicated in patients with a history of flucloxacillin-associated jaundice/hepatic dysfunction.
4.4 Special warnings and precautions for use
Before initiating therapy with co-fluampicil careful enquiries should be made concerning previous hypersensitivity reactions to P-lactam antibiotics.
Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported in patients receiving P-lactam antibiotics. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral therapy. These reactions are more likely to occur in individuals with a history of hypersensitivity to P-lactam antibiotics.
Co-fluampicil contains ampicillin and should be avoided if infectious mononucleosis and/or acute or chronic leukaemia of lymphoid origin are suspected. The occurrence of a skin rash has been associated with these conditions following the administration of ampicillin.
Co-fluampicil should be used with caution in patients with evidence of hepatic dysfunction (see section 4.8).
Special caution is essential in the newborn because of the risk of hyperbilirubinemia. Studies have shown that, at high dose following parenteral administration, flucloxacillin can displace bilirubin from plasma protein binding sites, and may therefore predispose to kernicterus in a jaundiced baby. In addition, special caution is essential in the newborn because of the potential for high serum levels of Flucloxacillin due to a reduced rate of renal excretion.
During prolonged treatments (e.g osteomyelitis, endocarditis), regular monitoring of hepatic and renal functions is recommended.
Prolonged use may occasionally result in the selection of resistant strains of organisms.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.
Sodium Content: Co-Fluampicil Suspension contains 12.3mg Sodium per 5ml of Oral Suspension. This should be included in the daily allowance of patients on sodium restricted diets
4.5 Interaction with other medicinal products and other forms of interaction
Bacteriostatic drugs may interfere with the bactericidal action of ampicillin and flucloxacillin.
In common with other oral broad-spectrum antibiotics, co-fluampicil may reduce the efficacy of oral contraceptives and patients should be warned accordingly.
Probenecid decreases the renal tubular secretion of co-fluampicil. Concurrent use with co-fluampicil may result in increased and prolonged blood levels of both ampicillin and flucloxacillin.
Concurrent administration of all allopurinol during treatment with ampicillin can increase the likelihood of allergic skin reactions.
Co-fluampicil contains ampicillin. It is recommended that when testing for the presence of glucose in urine during ampicillin treatment, enzymatic glucose oxidase methods should be used because false positive readings are common with chemical methods due to the high urinary concentrations of ampicillin.
4.6 Fertility, pregnancy and lactation
Pregnancy: Animal studies with co-fluampicil have shown no teratogenic effects. The product has been in clinical use since 1971 and the limited number of reported cases of use in human pregnancy have shown no evidence of untoward effects. The decision to administer any drug during pregnancy should be taken with the utmost care. Therefore co-fluampicil should only be used in pregnancy when the potential benefits outweigh the potential risks associated with treatment.
Lactation: Trace quantities of penicillin, ampicillin and flucloxacillin can be detected in breast milk. The possibility of hypersensitivity reactions must be considered in breast-fed infants. Therefore co-fluampicil should only be administered to a breastfeeding mother when the potential benefit outweigh the potential risks associated with treatment.
4.7 Effects on ability to drive and use machines
No known adverse effects on the ability to drive or operate machinery have been observed.
4.8 Undesirable effects
Side effects, as with other penicillins, are uncommon and mainly of a mild and transitory nature. ) . An urticarial rash suggests penicillin hypersensitivity; an erythematous rash may arise in patients receiving ampicillin who have glandular fever
Renal effects:
Interstitial nephritis can occur rarely but it is reversible when treatment is discontinued.
Haematological effects:
As with other p-lactam antibiotics, haematological effects including reversible leucopenia, reversible thrombocytopenia and haemolytic anaemia have been report rarely.
Hypersensitivity reactions:
If any hypersensitivity reaction (e.g skin rash) occurs, the treatment should be discontinued.
Skin rash, puritis and urticaria have been reported occasionally. The incidence of rash is higher in patients suffering from infectious mononucleosis and acute or chronic leukaemia of lymphoid origin. Purpura, fever, eosinophilia and sometimes angioneurotic oedema have also been reported. Rarely, skin reactions such as erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported. Reactions such as fever, arthralgia and myalgia can develop more than 48 hours after the start of the treatment.
Anaphylaxis (see Item 4.4 -Warnings) has been reported rarely.
Gastrointestinal reactions:
Minor gastrointestinal disturbances, including occasionally nausea, vomiting and diarrhoea may occur during treatment. Pseudomembranous colitis has been reported rarely.
Hepatic effects:
Hepatitis and cholestatic jaundice have been reported rarely. These may be delayed for up to two months after withdrawal of treatment. In some cases the course of these conditions has been protracted and lasted for several months. Very rarely deaths have been reported from hepatic effects but are mostly limited to patients with serious underlying disease.
A moderate transient increase in transaminases has been reported.
Overdose
4.9
Problems of over dosage with co-fluampicil are unlikely to occur; if encountered they may be treated symptomatically.
Gastrointestinal effects such as nausea, vomiting and diarrhoea may be evident and should be treated symptomatically.
Co-fluampicil contains flucloxacillin. Haemodialysis does not lower the serum levels of flucloxacillin.
Co-fluampicil contains ampicillin, which may be removed from the circulation by haemodialysis.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Fluclaxacillin is used for the treatment of infections due to staphylococci resistant to
benzylpenicillin. It is also used for the mixed streptococcal infections when the staphylococci are penicillin-resistant.
Ampicillin is a broad spectrum antibiotic which is bactericidal for both gram positive and gram negative bacteria.
5.2 Pharmacokinetic properties
Flucloxacillin after an oral dose of 250 to 500 mg in fasting subjects shows peak serum concentrations at one hour ranging from 3-27 mcg/ml with a mean peak 11-15 mcg/ml. Therapeutic concentrations persist for about four hours. Doubling the dose can double the plasma concentrations. About 95% of flucoxacillin is metabolised to a limited extent and the unchanged drug and metabolites are excreted in the urine.
Ampicillin is relatively stable in gastric secretion and is well absorbed from the gastro-intestinal tract producing peak concentrations in about two hours. Doubling the dose can produce double the concentration. Ampicillin diffuses across the placenta and the foetal circulation and concentrations can persist in amniotic fluid. Concentrations can be detected in the milk of nursing mothers. There is little diffusion into the cerebro-spinal fluid except when the meninges are infected, when high concentrations are achieved. Concentrations of ampicillin are found in ascetic, pleural, joint and ocular fluids. 30% of the orally administered dose is excreted unchanged in the urine in about six hours.
Preclinical safety data
5.3
Not applicable
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sodium benzoate BP
Disodium edetate BP
Saccharin sodium BP
Mono-ammonium glycyrrhizinate HSE
Sodium citrate (dried) BP
Flavour apricot HSE
Flavour menthol HSE
Yellow F.D. & C.No:6 (E110) HSE
Sucrose (Caster) BP
6.2 Incompatibilities
None known
6.3 Shelf life
24 months unopened 7 days after reconstitution
6.4 Special precautions for storage
Store in a cool dry place at a temperature not exceeding 25°C
6.5 Nature and contents of container
High density polyethylene bottles with tamper-evident and child-resistant cap or Amber Beatson Clark Winchester with polypropylene screw cap. Each pack contains 100ml when reconstituted.
6.6 Special precautions for disposal
No special instructions.
7 MARKETING AUTHORISATION HOLDER
Zecare Ltd
Unit5 Blenheim Court, Brownfields Welwyn Garden City,
Hertfordshire AL7 1AN
8 MARKETING AUTHORISATION NUMBER(S)
PL 24581/0034
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Granted 29.10.85 / Renewed 11.04.91 / Renewed 15.05.96
10 DATE OF REVISION OF THE TEXT
18/10/2012